曲美他嗪治疗稳定型心绞痛合并糖尿病疗效观察

Clinical effect of trimetazidine in patients with stable angina pectoris and diabetes

目的探讨曲美他嗪(trimetazidine)在稳定型心绞痛合并2型糖尿病患者中的临床疗效。方法选取我院2000年1月～2004年9月102例心绞痛合并糖尿病患者,随机分为常规口服药物治疗组(A组)和曲美他嗪组(B组)。B组在常规口服药物基础上加曲美他嗪20mg,每日3次,持续4周。在服药前以及服药期间每周随诊观察,共4周,询问病史及进行运动负荷(平板)试验。结果患者全部完成疗程,2例服药后有轻微上腹部不适但无需停药。B组胸痛发作每周次数减少(4.2±0.5)次,而A组减少(2.1±0.8)次,两组相比差异有统计学差异(P<0.05)。B组病人硝酸甘油消耗量平均减少(6.1±0.7)片,A组病人平均减少(3.3±0.9)片(P<0.05)。运动平板试验持续时间B组病人增加(63.6±2.3)秒,A组病人增加(31.6±2.2)秒(P<0.05)。结论在传统药物治疗的基础上联用曲美他嗪,可以使稳定型心绞痛合并糖尿病患者受益,且病人耐受良好。

Objectives To evaluate the therapeutic efficacy of trimetazidine in patients with stable angina pectoris and diabetes. Methods A total of 102 diabetic patients with stable angina were divided into two groups randomly:traditional medicine therapy group(A) and trimetazidine therapy group(B) from January 2000 to September 2004. Patients in B group were received a stabilization, 4 week therapy with trimetazidine,20 mg three times daily. Some clinical data such as blood pressure and treadmill exercise test were compared before taking medicine and every week later in the total of 4 weeks. Results All patients completed the follow-up. Two cases were somewhat stomachaches sometimes, but no one stopped the therapy within the study. During the follow-up, the times of the anginal attacks in every week dereased by (4.2±0.5) in B group, but (2.1±0.8) in A group(P<0.05); the consumption of nitroglycerine pills reduced by (6.1±0.7) in B group, and in A group (3.3±0.9)(P<0.05).The total time of exercise was increased by (63.6±2.3)s in B group, and in A group (31.6±2.2)s. Conclusions In the base of traditional haemodynamic medical therapy, patients with stable angina pectoris and diabetes will benefit from trimetazidine therapy. Trimetazidine has good security and tolerance.